Damora Therapeutics, Inc.

NASDAQ:DMRA

Biotechnology

Healthcare
$22.98 +0.34%

+$0.07 today

Market cap
$1.42B
Beta
1.48
P/E (TTM)
-0.1
EPS (TTM)
-$177.15
52W Low $2.45High $38.33

Volume 0.58M

Average 0.33M

Returns on capital

Damora Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-87.3%

avg -80.8%

ROIC

-87.7%

avg -73.7%

ROA

-80.5%

avg -70.3%

Analysis

ROA is currently the strongest return metric at -80.5% versus its period average of -70.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Garrett Winslow

Senior VP, General Counsel & Corporate SecretaryUSD 827.8K472.29K<0.01%

Becker Hewes

Chief Medical Officer—60——

Sherwin Sattarzadeh

Chief Operating Officer—47——

Brian Burkavage

Senior VP of Finance, Principal Financial & Accounting Officer—43312.54K0.51%

Hakon Leffler

Co-Founder————

Tariq Sethi FRCP

Co-Founder————

Jennifer A. Jarrett

CEO, President & Director—55——

Ulf J. Nilsson

Co-Founder————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 6, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

1

$252,875.00

Sells

1

$7,345.10

Net Transaction Value

+$245,529.90

Net buying

Most Active

Jarrett Jennifer

1 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Sep 25, 26

Jarrett Jennifer

Direct

Buy$252.9K
Jul 6, 26

Winslow Garrett

Direct

Sell$7.3K

Summary

Insiders reported 1 buys worth $252,875.00 and 1 sells worth $7,345.10 over the last 12 months. That adds up to net buying of $245,529.90. Jarrett Jennifer was the most active insider with 1 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A6 analysts
Net IncomeN/AN/AN/A
N/A6 analysts
EBITN/AN/AN/A
N/A6 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Damora Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about DMRA's management, answered from reported figures.

Who manages DMRA?

Damora Therapeutics, Inc. (DMRA) lists 8 active executives. The top listed executive is Garrett Winslow, Senior VP, General Counsel & Corporate Secretary.

Are DMRA insiders buying or selling?

Recent insider activity shows net buying of $49.50M.